Literature DB >> 11566256

An unusual intronic mutation in the CYBB gene giving rise to chronic granulomatous disease.

D Noack1, P G Heyworth, P E Newburger, A R Cross.   

Abstract

The most common, X-linked, form of chronic granulomatous disease (CGD) is caused by mutations in the CYBB gene located at Xp21.1. The product of this gene is the large subunit of flavocytochrome b558, gp91phox, which forms the catalytic core of the antimicrobial superoxide-generating enzyme, NADPH oxidase. In the overwhelming majority of cases, mutations are family-specific and occur in the exonic regions of the gene, or more rarely at the intron/exon borders. Alternatively, they are large (often multi-gene) deletions. In addition, four mutations have been found in the promoter region. In contrast, very few intronic mutations have been reported. Here we describe an intronic mutation that causes X-linked CGD. A single nucleotide substitution in the middle of intron V creates a novel 5' splice site and results in multiple abnormal mRNA products.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11566256     DOI: 10.1016/s0925-4439(01)00065-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

Review 1.  Hematologically important mutations: X-linked chronic granulomatous disease (third update).

Authors:  Dirk Roos; Douglas B Kuhns; Anne Maddalena; Joachim Roesler; Juan Alvaro Lopez; Tadashi Ariga; Tadej Avcin; Martin de Boer; Jacinta Bustamante; Antonio Condino-Neto; Gigliola Di Matteo; Jianxin He; Harry R Hill; Steven M Holland; Caroline Kannengiesser; M Yavuz Köker; Irina Kondratenko; Karin van Leeuwen; Harry L Malech; László Marodi; Hiroyuki Nunoi; Marie-José Stasia; Anna Maria Ventura; Carl T Witwer; Baruch Wolach; John I Gallin
Journal:  Blood Cells Mol Dis       Date:  2010-08-21       Impact factor: 3.039

2.  Use of antisense oligonucleotides to correct the splicing error in ISCU myopathy patient cell lines.

Authors:  Gregory P Holmes-Hampton; Daniel R Crooks; Ronald G Haller; Shuling Guo; Susan M Freier; Brett P Monia; Tracey A Rouault
Journal:  Hum Mol Genet       Date:  2016-12-01       Impact factor: 6.150

Review 3.  Deep intronic mutations and human disease.

Authors:  Rita Vaz-Drago; Noélia Custódio; Maria Carmo-Fonseca
Journal:  Hum Genet       Date:  2017-05-12       Impact factor: 4.132

4.  Long polymerase chain reaction-based fluorescence in situ hybridization analysis of female carriers of X-linked chronic granulomatous disease deletions.

Authors:  Kelly Claire Simon; Deborah Noack; Julie Rae; John Curnutte; Shireen Sarraf; Valentin Kolev; Jan K Blancato
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

5.  Late diagnosis and advances in genetics of chronic granulomatous disease.

Authors:  G Di Matteo; A Finocchi
Journal:  Clin Exp Immunol       Date:  2020-12-13       Impact factor: 4.330

Review 6.  Defective splicing, disease and therapy: searching for master checkpoints in exon definition.

Authors:  Emanuele Buratti; Marco Baralle; Francisco E Baralle
Journal:  Nucleic Acids Res       Date:  2006-07-19       Impact factor: 16.971

Review 7.  Role of pseudoexons and pseudointrons in human cancer.

Authors:  Maurizio Romano; Emanuele Buratti; Diana Baralle
Journal:  Int J Cell Biol       Date:  2013-09-24

8.  Functional Restoration of gp91phox-Oxidase Activity by BAC Transgenesis and Gene Targeting in X-linked Chronic Granulomatous Disease iPSCs.

Authors:  Magdalena Laugsch; Maria Rostovskaya; Sergiy Velychko; Cornelia Richter; Ariane Zimmer; Barbara Klink; Evelin Schröck; Michael Haase; Katrin Neumann; Sebastian Thieme; Joachim Roesler; Sebastian Brenner; Konstantinos Anastassiadis
Journal:  Mol Ther       Date:  2015-08-28       Impact factor: 11.454

9.  Analysis of Pathogenic Pseudoexons Reveals Novel Mechanisms Driving Cryptic Splicing.

Authors:  Niall P Keegan; Steve D Wilton; Sue Fletcher
Journal:  Front Genet       Date:  2022-01-24       Impact factor: 4.772

Review 10.  Recent advances in primary immunodeficiency: from molecular diagnosis to treatment.

Authors:  Giorgia Bucciol; Isabelle Meyts
Journal:  F1000Res       Date:  2020-03-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.